Opendata, web and dolomites

PD-MIND SIGNED

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PD-MIND" data sheet

The following table provides information about the project.

Coordinator
KING'S COLLEGE LONDON 

Organization address
address: STRAND
city: LONDON
postcode: WC2R 2LS
website: www.kcl.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 2˙131˙609 €
 EC max contribution 999˙698 € (47%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2022-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KING'S COLLEGE LONDON UK (LONDON) coordinator 524˙820.00
2    THE UNIVERSITY OF EXETER UK (EXETER) participant 184˙398.00
3    STICHTING LYGATURE NL (UTRECHT) participant 100˙937.00
4    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 58˙125.00
5    UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA IT (CHIETI) participant 58˙125.00
6    Masarykova univerzita CZ (BRNO STRED) participant 40˙625.00
7    HELSE STAVANGER HF NO (STAVANGER) participant 16˙417.00
8    NORGES PARKINSONFORBUND NO (OSLO) participant 16˙250.00
9    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
10    PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG UK (LONDON) participant 0.00

Map

 Project objective

Parkinson Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. There is an unmet clinical need to treat Parkinson disease with mild cognitive impairment (PD-MCI). There is ample evidence from epidemiological studies as well as (pre)clinical research that Nicotinic receptors are involved in PD and cognition. Recently a clinical trial suggested that selective α7 nicotinic receptor agonist improved cognition in PD patients, as a secondary outcome measure. Hence, the main goal of PD-MIND is to show the potential of the Astrazeneca nicotinic α7 agonist AZD0328 in a randomized, placebo-controlled, international multicentre, cross-over study on cognition in people diagnosed with PD-MCI. We will assess the Attention Intensity Index composite score from the CogTrackTM system as primary outcome measure and other clinical aspects (cognition, motor symptoms) as secondary outcomes. In addition, blood, CSF and imaging biomarkers will be assessed as potential predictors of response, and as marker of target involvement. Patients (Public and Patient Involvement) and other stakeholders will be engaged from the start to allow integration of end-user perspectives in the design and execution of the project. PD-MIND will put considerably effort to disseminate and exploit clinical outcome data and biomarker results, and to sustain the partnership for subsequent phase 3 clinical studies. PD-MIND consortium consist of world-leading PD-MCI experts in the area of clinical trials, clinical coordination, project management, data management and analysis, and biomarkers. As such the consortium is well positioned to execute the proposed work and complement the EFPIA members.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PD-MIND" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PD-MIND" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

STOPFOP (2019)

Saracatinib Trial tO Prevent FOP

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More  
relatedResult rcn (647443) AGGIORNATO correttamente
lastchecktime (2020-10-31 10:33:58) correctly updated